- Home
- ATNM
as 05-23-2025 1:31pm EST
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 43.7M | IPO Year: | N/A |
| Target Price: | $4.67 | AVG Volume (30 days): | 319.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $8.81 | Next Earning Date: | 05-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Actinium Pharmaceuticals Inc. (Delaware) News
ATNM Breaking Stock News: Dive into ATNM Ticker-Specific Updates for Smart Investing
Associated Press Finance
14 days ago
Actinium: Q1 Earnings Snapshot
PR Newswire
17 days ago
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
PR Newswire
25 days ago
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
PR Newswire
25 days ago
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
PR Newswire
2 months ago
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
PR Newswire
2 months ago
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
PR Newswire
2 months ago
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
MT Newswires
2 months ago
Actinium Pharmaceuticals Signs Actinium-225 Supply Deal With Eckert & Ziegler
Compare ATNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATNM Actinium Pharmaceuticals Inc. (Delaware) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.